Gabelli Weighs in on Cempra, Inc.’s FY2017 Earnings (MLNT)

Cempra, Inc. (NASDAQ:MLNT) – Equities research analysts at Gabelli cut their FY2017 EPS estimates for Cempra in a note issued to investors on Thursday. Gabelli analyst K. Kedra now expects that the biotechnology company will post earnings of ($5.60) per share for the year, down from their prior estimate of ($5.00). Gabelli has a “Hold” rating on the stock. Gabelli also issued estimates for Cempra’s FY2018 earnings at ($4.70) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($1.05) EPS and FY2021 earnings at $0.75 EPS.

Other research analysts have also recently issued reports about the company. Roth Capital cut Cempra from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $8.00 to $4.00 in a research report on Thursday, August 10th. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price objective on shares of Cempra in a report on Thursday, August 10th. Zacks Investment Research cut Cempra from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Jefferies Group reissued a “hold” rating and set a $3.00 price objective on shares of Cempra in a report on Thursday, September 14th. Finally, ValuEngine cut Cempra from a “sell” rating to a “strong sell” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Cempra has a consensus rating of “Hold” and a consensus price target of $6.05.

Cempra (NASDAQ:MLNT) opened at $16.20 on Monday. Cempra has a 12-month low of $10.25 and a 12-month high of $41.00. The company has a quick ratio of 11.49, a current ratio of 11.49 and a debt-to-equity ratio of 0.03.

ILLEGAL ACTIVITY NOTICE: “Gabelli Weighs in on Cempra, Inc.’s FY2017 Earnings (MLNT)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/04/gabelli-weighs-in-on-cempra-inc-s-fy2017-earnings-mlnt.html.

About Cempra

Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

What are top analysts saying about Cempra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cempra Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit